BioSpace News Archive

Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that three posters detailing the novel mechanistic activity of itolizumab were presented at the 2021 American Association of Immunologists (AAI) Annual Meeting held May 10-15, 2021

Further Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy CDMO Sector

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced the appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer.

Sonnet BioTherapeutics Holdings, Inc., a biopharmaceutical company developing innovative targeted biologic drugs, announced its financial results for the three months ended March 31, 2021 and provided a business update.

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF)(“Predictmedix” or the “Company”) is pleased to announce that Safe Entry Station units will be deployed at the North American tour of Hockeyfest in partnership with Juiceworks Exhibits (JUICEWORKS) and Jones Entertainment Grou

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announces that Nanox’s Chairman and Chief Executive Officer Ran Poliakine will make a presentation and the leadership team will host investor 1x1 meetings during the Berenberg Virtual Conference, which is being held May 18th through May 20th.

Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer

International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimer’s disease

Landos Biopharma, Inc and LianBio announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China and select Asian markets.